Profile data is unavailable for this security.
About the company
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-12.49m
- Incorporated2011
- Employees5.00
- LocationArtelo Biosciences Inc505 LOMAS SANTA FE, SUITE 160SOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 925-7049
- Websitehttps://artelobio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDT Equity Inc | 0.00 | -20.70m | 1.99m | 6.00 | -- | 0.3223 | -- | -- | -473.79 | -473.79 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -358.56 | -- | -- | -- | -- | -- | -- | -- | -- | -16.00 | 0.2881 | -- | -- | -- | -3,227.48 | -- | -- | -- |
| ABPRO Holdings Inc | 0.00 | -22.04m | 2.00m | 6.00 | -- | -- | -- | -- | -24.37 | -24.37 | 0.00 | -6.04 | 0.00 | -- | -- | 0.00 | -467.23 | -- | -- | -- | -- | -- | -- | -- | -- | -4.82 | -- | -- | 50.00 | -- | -48.72 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -3.95m | 2.14m | 2.00 | -- | 0.356 | -- | -- | -7.30 | -7.30 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -75.76 | -86.22 | -80.46 | -561.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.15 | -- | -- | -- |
| Azitra Inc | 0.00 | -11.12m | 2.15m | 12.00 | -- | 0.4914 | -- | -- | -5.49 | -5.49 | 0.00 | 0.4066 | 0.00 | -- | -- | 0.00 | -157.91 | -- | -203.88 | -- | -- | -- | -- | -- | -- | -- | 0.1197 | -- | -98.91 | -- | 29.05 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -13.07m | 2.15m | 4.00 | -- | 0.2006 | -- | -- | -130.83 | -130.83 | 0.00 | 17.25 | 0.00 | -- | -- | 0.00 | -135.60 | -153.00 | -197.11 | -237.57 | -- | -- | -- | -- | -- | -- | 0.0031 | -- | -- | -- | 21.18 | -- | -26.93 | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 2.32m | 13.00 | -- | 0.2752 | -- | 146.87 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Purminds Enterprises Inc | 0.00 | -77.46k | 2.36m | 0.00 | -- | 0.0654 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -12.49m | 2.42m | 5.00 | -- | -- | -- | -- | -20.88 | -20.88 | 0.00 | -0.407 | 0.00 | -- | -- | 0.00 | -219.08 | -- | -427.33 | -- | -- | -- | -- | -- | -- | -91.40 | 3.62 | -- | -- | -- | -5.78 | -- | -- | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.47m | 30.00 | -- | -- | -- | 4.11 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| BioRestorative Therapies Inc | 383.40k | -12.67m | 2.53m | 11.00 | -- | 1.04 | -- | 6.60 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
| InMed Pharmaceuticals Inc | 4.80m | -8.21m | 2.56m | 13.00 | -- | 0.197 | -- | 0.5336 | -7.21 | -7.21 | 2.65 | 4.45 | 0.4028 | 3.01 | 15.28 | -- | -68.93 | -87.37 | -78.82 | -107.49 | 33.69 | -- | -171.13 | -356.16 | 6.37 | -27.94 | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| Oragenics Inc | 0.00 | -10.90m | 2.74m | 3.00 | -- | 0.2756 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -63.41m | 2.85m | 1.00 | -- | 0.1976 | -- | -- | -45.47 | -45.47 | 0.00 | 1.08 | 0.00 | -- | -- | 0.00 | -702.98 | -- | -1,223.40 | -- | -- | -- | -- | -- | -- | -56.99 | 0.0422 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 31 Dec 2025 | 33.53k | 1.66% |
| Geode Capital Management LLCas of 31 Dec 2025 | 11.40k | 0.57% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 9.42k | 0.47% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.61k | 0.23% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 83.00 | 0.00% |
| Strategic Advisers LLCas of 30 Sep 2025 | 30.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 11.00 | 0.00% |
| UBS Financial Services, Inc.as of 31 Dec 2025 | 5.00 | 0.00% |
| Rothschild Investment LLCas of 31 Dec 2025 | 2.00 | 0.00% |
| City National Rochdale LLCas of 30 Sep 2025 | 1.00 | 0.00% |
